GATC Health

What GATC Health does

GATC Health is a privately held tech-bio company founded in 2020 and headquartered in Irvine, California (incorporated in Wyoming), with an additional AI/laboratory facility in Morgantown, West Virginia. The company develops and commercializes the proprietary Operon™ AI platform, which simulates human biochemistry across molecular, cellular, tissue, and organism-level scales using multi-omics data integration, neural networks, reinforcement learning, and a multi-scale digital twin architecture. Operon is positioned to predict drug candidate efficacy, safety, off-target effects, and clinical trial outcomes, with third-party validation from UC Irvine reporting 91% specificity and 86% sensitivity on Derisq™ AI Report outputs. A flagship internally derived candidate, GATC-1021 (a serotonin receptor-targeting therapy for opioid use disorder), is moving toward IND after peer-reviewed publication in PNAS.

The commercial product portfolio is built around two core offerings: the Operon™ platform (typically accessed via Master Services Agreements) and the Derisq™ AI Report, a 30-40 page risk intelligence deliverable produced in 3-6 weeks. Revenue is generated through project-based Derisq engagements with upfront payments and success-based contingent bonuses, multi-project MSAs with clinical-stage biopharmaceutical companies, strategic co-development and licensing arrangements (e.g., Lisata Therapeutics), and a uniquely structured clinical trial insurance product underwritten by MCI through Lloyd's of London for which GATC's Operon is the exclusive AI engine. Target customers are biotech companies seeking pipeline de-risking, large pharma companies optimizing R&D capital allocation, and institutional investors requiring objective drug-candidate risk assessment for due diligence, with secondary engagement in government/public-health programs (notably West Virginia for opioid abatement) and academic collaborations.

The business is supported by an 11-50 person organization led by CEO John Stroh (investment banking and M&A background), President Dr. Rahul Gupta (former White House Drug Czar), CTO/Chairman Jayson Uffens, and a senior team including PhD-level scientists from Pfizer, Roche, and Ionis, an IBM Watson-trained Head of AI Engineering, and a CIO with 150+ patents. Strategic distribution runs through direct enterprise sales, a Bioneex marketplace integration, the BioAtla-linked $40M Inversagen AI joint venture, and ongoing engagement at JPM Healthcare, Fierce Biotech Week, and Biocom Converge. As of February 2026 the company has raised approximately $15 million from private investors across multiple Regulation D exempt offerings.

Name

GATC Health

Legal name

GATC Health, Inc.

Website

https://gatchealth.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

GATC Health is a privately held tech-bio company that applies its proprietary Operon AI platform and multi-scale digital twin architecture to simulate human biochemistry and predict drug candidate efficacy, safety, and clinical trial outcomes for biotech, pharmaceutical, and institutional investor clients.

Ownership category

akta.pro rank

Product category

AI-driven Drug Discovery Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM), Clinical Pharmacology & Pharmacometrics (Modeling & Simulation) (HLAIALAG), Pharmacovigilance & Drug Safety Software (HLAGAJAK)

Keywords

• AI drug discovery
• Predictive drug assessment
• Multiomics analytics platform
• Clinical trial optimization
• Drug risk prediction

Headquarters

HQ city

Irvine

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Derisq™ AI Report Sales: GATC Health generates revenue through sales of Derisq AI reports to biotech companies, pharmaceutical partners, and investors. Reports are customized based on client needs with upfront payments and success-based contingent bonuses mentioned in client agreements. The company offers multiple reports per engagement with pricing based on scope of analysis.
2. Platform Services and Master Services Agreements: Revenue from multi-project service agreements with pharmaceutical companies deploying Operon platform for pipeline analysis. Includes Derisq reports evaluating drug candidates and regulatory feedback analysis. Terms include upfront payments plus success-based bonuses.
3. Partnership and Licensing Revenue: Revenue from strategic partnerships including joint ventures like Inversagen AI (with BioAtla) and licensing arrangements with companies like Lisata Therapeutics. The $40 million SPV with BioAtla represents structured funding for Phase 3 trial advancement with ownership stakes.
4. Clinical Trial Insurance Product: GATC Health's AI platform underpins a clinical trial insurance product underwritten by MCI through Lloyd's of London. While the primary insurance relationship is with MCI, GATC's predictive analysis enables this innovative financing structure, potentially generating revenue through the partnership.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

GATC Health operates the proprietary Operon AI platform that simulates human biochemistry using multi-omics data, neural networks, and machine learning to predict drug candidate efficacy, safety, and clinical trial outcomes, delivering 3-5 optimized compounds in 4-6 months. The company sells Derisq AI risk-assessment reports to biotech, pharma, and investor clients, and supports a clinical trial insurance product underwritten through Lloyd's of London.

Product overview

GATC Health offers a platform-plus-modules architecture centered on the Operon™ AI discovery engine and Derisq™ AI risk assessment report. Operon™ is a proprietary AI platform that simulates human biology to discover and generate novel drug candidates in 4-6 months, while Derisq™ delivers validated predictive analytics on drug candidate safety, efficacy, and off-target risks. The company also offers a clinical trial insurance product underwritten through Lloyd's of London, enabling financing protected by insurance for biotech companies whose drug candidates receive favorable Derisq analysis.

Differentiator

Problem solved

Functional benefit

Brands

• Operon™: Proprietary AI-powered discovery engine that simulates human biology to predict drug candidate efficacy, safety, and success rates.
• Derisq™

Products and services

• Operon Platform GATC Health's proprietary AI-powered discovery engine that simulates human biochemistry's billions of interactions to predict drug candidate efficacy, safety, and success rates. Delivers 3-5 optimized compounds ready for preclinical testing in 4-6 months, compared to 36-48 months for traditional methods. Used by biotech and pharmaceutical companies to accelerate and de-risk drug development.
• Derisq AI Report An AI-powered predictive risk intelligence report providing detailed predictions on drug candidate safety, efficacy, and off-target risks. Reports are 30-40 pages, delivered within 3-6 weeks, validated at 91% specificity and 86% sensitivity by UC Irvine, functioning as a FICO score for drug development decisions. Available to biotech companies, pharmaceutical partners, and biotech investors.
• Clinical Trial Insurance Product Insurance product underwritten by MCI through Lloyd's of London that reimburses clinical trial costs if safety or efficacy endpoints are not met, with GATC's Operon platform providing the underlying AI risk assessment. Enables new insurance-backed financing pathways for biotech companies whose drug candidates receive favorable Derisq analysis.

Quantifiable outcome

• 11x improvement over industry average in early-stage drug success predictions
• +5 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability6 records

Feature4 records

Partnerships

Ten partnerships are on record, tiered minor, core and secondary.

• Astr60minorGTM or Marketing Partner · 10 June 2026Webinar collaboration on 'Rethinking Risk — How AI Can Optimize Capital Allocation' featuring exclusive insights from RBC Healthcare Investment Banking on biotech financing landscape.
• Inversagen AIcoreStrategic or Co-development Partner · 8 January 2026$40 million SPV joint venture formed by GATC Health and BioAtla for Phase III trials of ozuriftamab vedotin and development of conditionally active biologic senolytic therapies. Equal partnership between GATC and BioAtla with 35% stake allocated to Inversagen AI operations.
• BioAtlacoreStrategic or Co-development Partner · 31 December 2025$40 million special purpose vehicle (SPV) transaction with GATC Health and Inversagen AI to advance ozuriftamab vedotin (Oz-V) into Phase 3 clinical trials for oropharyngeal squamous cell carcinoma. GATC and BioAtla as equal partners in Inversagen AI, with BioAtla retaining 65% ownership of Oz-V across solid tumor indications. Initial $5 million deployed immediately, remaining $35 million expected Q1 2026. Joint collaboration to co-develop longevity therapeutic using BioAtla's CAB platform with GATC's AI.
• Lisata TherapeuticscoreStrategic or Co-development Partner · 6 November 2025Licensing agreements and strategic business development collaboration applying AI-driven multiomics to drug development. Partnership expanded from cardiovascular indications to opioid use disorder (OUD) drug development. Lisata reports positive clinical data for certepetide with extended cash runway supporting continued collaboration.
• West Virginia (State Government)coreStrategic or Co-development Partner · 29 October 2025Partnership with the state of West Virginia to address disproportionate impact of opioid dependence in Appalachia through multiomics platform. GATC West Virginia lab strategically located near WVU campus in WVU Innovation Building. Collaboration with WVU Innovation Corporation for opioid abatement initiatives.
• WVU Innovation CorporationsecondaryStrategic or Co-development Partner · 29 October 2025Strategic collaboration with WVU Innovation Corporation supporting GATC's AI-powered lab operations in Morgantown, West Virginia. Enhancing AI lab operations near WVU campus for opioid research and drug development.
• BioneexsecondaryTechnology or Integration · 16 September 2025Integration partnership embedding GATC Health's AI-driven predictive analytics into Bioneex's marketplace platform for therapeutic assets. Provides advanced predictions of drug candidate performance including safety, efficacy, and off-target effects. Validated accuracy rates of 91% true positive and 86% true negative from UCI validation studies. Collaboration aims to streamline due diligence and deal flow for biopharma companies and venture capital investors.
• Lloyd's of London (MCI/Acrisure)coreStrategic or Co-development Partner · 18 March 2025Groundbreaking clinical trial insurance product underwritten by MCI through Lloyd's of London. GATC Health's Operon platform selected as exclusive AI platform for analysis supporting insurance-backed financing model for clinical trials. If insured trial fails to meet endpoints, Lloyd's reimburses the lender. First-of-its-kind product enabling new financing pathways for biotech companies. Extensive due diligence conducted before selection. Initial response from biotech companies and large brokerage firms exceeded expectations.
• Humane WorldminorStrategic or Co-development Partner · 18 March 2025Partnership with Humane Society's Humane World initiative. GATC selected as sole AI company in non-animal working group due to Operon platform training exclusively on human data. Supports FDA 2025 roadmap for phasing out animal testing and broader embrace of New Approach Methodologies (NAMs).
• Answer ALS / LADDIA InitiativesecondaryStrategic or Co-development Partner · 1 January 2025LADDIA initiative - AI drug development collaboration with GATC Health, Pennington Biomedical Research Center, and Tulane University. Applying AI and machine learning to the massive Neuromine dataset to identify distinct ALS subtypes and pinpoint specific drug targets. Goal to bring precision medicine approach to ALS treatment similar to oncology revolution.

Scale indicators12 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology with machine learning to identify novel therapeutics. Closely comparable to GATC's Operon platform in using AI/ML to generate and validate drug candidates.
• Insitro: Machine learning-driven drug discovery company combining wet-lab biology with predictive models. Direct competitor to GATC's approach of using AI for in silico prediction of drug efficacy and safety.
• Exscientia: AI-native pharma using end-to-end platform to design and develop drug candidates. Direct peer with similar value proposition of compressing timelines and improving success rates through AI.
• Schrödinger: Physics-based computational chemistry and AI platform for molecular design and drug discovery. Overlaps with GATC's predictive analytics approach to drug candidate evaluation and optimization.
• Atomwise: AI-driven small molecule drug discovery using structure-based deep learning. Direct competitor in the AI/ML-for-drug-discovery space with similar pharma partnership and licensing revenue model.
• XtalPi: AI and quantum physics-based drug discovery platform that predicts drug properties and crystal structures. Comparable AI-driven prediction approach with multi-omics and physics-based modeling.
• BenevolentAI: AI-driven drug discovery company using knowledge graphs and machine learning to identify new drug targets and candidates. Similar predictive analytics approach with pharma partnership revenue model.

Emerging players

• Lantern Pharma: AI-driven oncology drug development using machine learning and genomics to identify and advance therapeutic candidates. Comparable AI approach with focus on oncology indications similar to GATC's BioAtla partnership.
• Owkin: AI biotech combining machine learning with multimodal patient data to accelerate drug development and clinical trials. Overlaps with GATC's digital twin architecture and clinical trial optimization capabilities.
• Verge Genomics: AI-driven drug discovery using human genomics and machine learning to identify therapeutic targets. Comparable in using human-only data for AI model training, similar to GATC's Operon platform.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@GATCHealth
• LinkedInlinkedin.com/company/gatc-health

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GATC Health